TG Therapeutics (TGTX) Q1 2026 earnings summary

Executive summary

• Q1 2026 delivered record-setting results, with global revenue reaching $205 million and U.S. BRIUMVI net revenue at $195 million, up 63% year-over-year, driven by strong demand and commercial execution.

• Over 25,000 patients have been prescribed BRIUMVI globally, marking a shift from early adoption to a growing installed base.

• Full-year 2026 global revenue guidance raised to $925 million; U.S. BRIUMVI revenue guidance increased to $885–900 million.

• A new $750 million senior secured credit facility was secured, repaying the prior $250 million facility and providing additional liquidity.

• Strategic focus remains on expanding BRIUMVI's reach through lifecycle programs, pipeline advancement, and disciplined capital allocation.

Financial highlights

• Q1 2026 net product revenue was $201.3 million, up from $119.7 million in Q1 2025; total revenue reached $205 million, including $3.6 million in license, royalty, and other revenue.

• Operating income reached $34.8 million, compared to $8.6 million in Q1 2025.

• Net income was $19.8 million ($0.12 per diluted share), up from $5.1 million ($0.03 per share) a year ago.

• Cash, cash equivalents, and investment securities totaled $572.8 million as of March 31, 2026.

• Share buybacks totaled $100 million in Q1, with the program expanded to $300 million.

Outlook and guidance

• Full-year 2026 global revenue guidance raised to $925 million; U.S. BRIUMVI revenue guidance increased to $885–900 million.

• Q2 2026 U.S. BRIUMVI net revenue guidance set at approximately $220 million.

• Full-year operating costs expected at $350 million (excluding stock-based comp), plus $100 million for subcutaneous manufacturing and secondary manufacturer startup.

• Topline data from the Phase 3 subcutaneous BRIUMVI trial expected by year-end 2026 or Q1 2027, with commercial launch targeted for 2028 pending regulatory approval.

• Existing cash, equivalents, and projected revenues expected to fund operations for more than twelve months.